Opus Genetics (NASDAQ:IRD) Given Buy Rating at BTIG Research

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a report released on Wednesday, Benzinga reports. They presently have a $12.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 119.14% from the stock’s previous close.

Several other research analysts have also recently issued reports on the stock. Guggenheim started coverage on shares of Opus Genetics in a report on Thursday, June 4th. They set a “buy” rating and a $16.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Opus Genetics in a research report on Wednesday, June 17th. Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Zacks Research raised shares of Opus Genetics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.69.

Opus Genetics Trading Up 26.2%

Shares of IRD traded up $1.14 during midday trading on Wednesday, reaching $5.48. 35,038,599 shares of the stock were exchanged, compared to its average volume of 1,168,929. Opus Genetics has a 52 week low of $1.32 and a 52 week high of $7.07. The company’s 50 day moving average is $3.79 and its two-hundred day moving average is $4.29. The company has a market capitalization of $452.59 million, a P/E ratio of -4.04 and a beta of 0.58.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $2.63 million. Opus Genetics had a negative return on equity of 338.88% and a negative net margin of 1,091.82%. On average, sell-side analysts expect that Opus Genetics will post -0.99 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert Gagnon sold 28,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total transaction of $127,120.00. Following the completion of the sale, the chief financial officer owned 556,375 shares of the company’s stock, valued at $2,525,942.50. This represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer owned 1,731,869 shares of the company’s stock, valued at approximately $5,109,013.55. This trade represents a 0.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 57,331 shares of company stock valued at $213,749 in the last three months. 11.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Opus Genetics

A number of institutional investors have recently made changes to their positions in IRD. Trails Edge Capital Partners LP acquired a new position in Opus Genetics during the 2nd quarter valued at approximately $11,276,434. BlackRock Inc. acquired a new stake in shares of Opus Genetics during the second quarter worth $12,809,000. ADAR1 Capital Management LLC acquired a new stake in shares of Opus Genetics during the second quarter worth $7,331,000. Nantahala Capital Management LLC purchased a new stake in shares of Opus Genetics during the second quarter valued at $12,582,185. Finally, AWM Investment Company Inc. purchased a new stake in shares of Opus Genetics during the second quarter valued at $956,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Promising OPGx-BEST1 results: In the low-dose first cohort of the Phase 1/2 BIRD-1 trial, all five participants showed clinically meaningful improvements in visual function. Three of five patients recorded meaningful best-corrected visual-acuity improvements, while retinal-sensitivity improvements were observed in three of four evaluable patients. No serious adverse events or dose-limiting toxicities were reported. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: FDA alignment improves development outlook: Following a Type C meeting, the FDA agreed that at least a three-decibel microperimetry improvement combined with patient-reported outcomes could serve as a potential pivotal-trial endpoint. Cohort 2 was over-enrolled, with dosing expected to finish in the fourth quarter of 2026 and initial three-month data anticipated in the second quarter of 2027. The company said its cash runway extends into 2029, potentially supporting multiple development milestones and possible priority-review-voucher opportunities. FDA Type C Meeting and Clinical Trial Update
• Positive Sentiment: Analyst support and options activity: Chardan Capital reaffirmed its “buy” rating and maintained a $13 price target, implying substantial upside from recent trading levels. Call-option purchases reached 4,820 contracts, about 681% above typical volume, reflecting heightened bullish speculation, although options activity can also increase volatility.
• Neutral Sentiment: Insider transaction: CFO Robert Gagnon sold 28,000 shares for approximately $127,120. The filing stated that the sale covered tax-withholding obligations tied to vested equity awards, reducing its bearish significance; he still held 556,375 shares afterward. Opus Genetics CFO Stock Sale

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.